title: The fusion protein of HSP65 with tandem repeats of beta-hCG acting as a potent tumor vaccine in suppressing hepatocarcinoma.
abstract: It has been demonstrated that the beta-subunit of human chorionic gonadotropin (beta-hCG) is ectopically expressed on a variety of human cancers of different histological types and has been used as an antigenic target in anti-cancer vaccines. We engineered a fusion protein by fusing 10 tandemly repeated copies of the 10-residue sequence of beta-hCG (109-118) (in CTP37) combined with beta-hCG C-terminal 37 peptides to mycobacterial heat-shock protein 65 and immunized mice via subcutaneous injection. Humoral immune and cellular immune responses were effectively elicited. High titer of anti-beta-hCG antibody was detected in immunized mice sera by ELISA and verified by Western blot analyses. The fusion protein of HSP65-X10-beta-hCGCTP37 effectively inhibited the growth of tumor both protective and therapeutic anti-tumor immunity in hepatocellular carcinoma tumor models in mice. Meanwhile, it also attenuated tumor-induced angiogenesis in intradermal tumor model in mice. Taken together, these results demonstrate that immune responses are effectively induced by a novel fusion protein vaccine targeting beta-hCG, suppressing the growth of hepatocellular carcinoma in mice. The beta-hCG-targeted vaccine holds promise for the treatment of a number of cancers and merits further study.
authors.affiliation: Minigene Pharmacy Laboratory, Biopharmaceutical College, China Pharmaceutical University, Tongjia Xiang 24, Nanjing, 210009, PR China.
authors.forename: Hu
authors.initials: H
authors.lastname: Xiangbing
authors.forename: Zhang
authors.initials: Z
authors.lastname: Yankai
authors.forename: Lin
authors.initials: L
authors.lastname: Ming
authors.forename: Lu
authors.initials: L
authors.lastname: Yong
authors.forename: Zhang
authors.initials: Z
authors.lastname: Yu
authors.forename: Zhang
authors.initials: Z
authors.lastname: Huiyong
authors.forename: Chen
authors.initials: C
authors.lastname: Yingying
authors.forename: Hou
authors.initials: H
authors.lastname: Jing
authors.forename: Xing
authors.initials: X
authors.lastname: Yun
authors.forename: Jin
authors.initials: J
authors.lastname: Liang
authors.forename: Cao
authors.initials: C
authors.lastname: Rongyue
authors.forename: Liu
authors.initials: L
authors.lastname: Jingjing
mesh_terms: D000818:Animals; D000912:Antibodies, Neoplasm / Q000276:immunology; D000918:Antibody Specificity / Q000276:immunology; D001426:Bacterial Proteins / Q000235:genetics / Q000276:immunology* / Q000627:therapeutic use; D019496:Cancer Vaccines / Q000235:genetics / Q000276:immunology* / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000276:immunology / Q000628:therapy*; D018834:Chaperonin 60 / Q000235:genetics / Q000276:immunology* / Q000627:therapeutic use; D018997:Chorionic Gonadotropin, beta Subunit, Human / Q000235:genetics / Q000276:immunology* / Q000627:therapeutic use; D008113:Liver Neoplasms / Q000276:immunology / Q000628:therapy*; D008297:Male; D051379:Mice; D009389:Neovascularization, Pathologic / Q000276:immunology; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000276:immunology* / Q000627:therapeutic use; D020080:Tandem Repeat Sequences
chemical_list: D000912:Antibodies, Neoplasm; D001426:Bacterial Proteins; D019496:Cancer Vaccines; D018834:Chaperonin 60; D018997:Chorionic Gonadotropin, beta Subunit, Human; D011993:Recombinant Fusion Proteins; C074119:heat-shock protein 65, Mycobacterium